Aurinia Pharmaceuticals Inc.
CAFinancials
Valuation Metrics
Aurinia Pharmaceuticals Inc.'s Market Cap is $2.17B. At end of 2025 it was $2.14B. Ranked #1961 of 3,121 in US market (top 63%), #745 of 1,463 on NASDAQ (top 51%), #130 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 49%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.17B | US#1,961/3,121 Sec#130/266 |
| Revenue | $312M | US#2,444/3,121 Sec#94/266 |
| Net Income | $314M | US#1,071/3,121 Sec#36/266 |
| Total Assets | $792M | US#2,576/3,121 Sec#120/266 |
| Net Assets | $615M | US#2,098/3,121 Sec#94/266 |
| Employees | 128 | US#2,583/3,121 Sec#161/266 |
| Value | ||
| P/E | 6.92x | US#128/3,121 Sec#6/266 |
| P/B | 3.53x | US#1,908/3,121 Sec#100/266 |
| PEG | 0.02x | US#50/3,121 Sec#6/266 |
| P/S | 6.98x | US#2,540/3,121 Sec#97/266 |
| EV/EBITDA | 10.91x | US#962/3,121 Sec#31/266 |
| FCF Yield | 7.99% | US#864/3,121 Sec#27/266 |
| Profitability | ||
| ROE | 51.09% | US#105/3,121 Sec#8/266 |
| ROA | 39.65% | US#16/3,121 Sec#5/266 |
| Op. Margin | 48.39% | US#141/3,121 Sec#5/266 |
| Revenue Growth | 19.76% | US#705/3,121 Sec#77/266 |
| Earnings Growth | 418.03% | US#88/3,121 Sec#6/266 |
| Financial Health | ||
| Debt Ratio | 28.85% | US#317/3,121 Sec#101/266 |
| Total Debt | $60M | US#2,572/3,121 Sec#147/266 |
| FCF | $174M | US#1,466/3,121 Sec#51/266 |
| Cash | $180M | US#1,819/3,121 Sec#122/266 |
| Current Ratio | 5.42x | US#435/3,121 Sec#135/266 |
| Net Debt/EBITDA | -0.63x | US#354/3,121 Sec#24/266 |
| Performance | ||
| 1Y Return | 31.11% | US#750/3,121 Sec#123/266 |
| 1M Return | 4.51% | US#219/3,121 Sec#25/266 |
| From 52W High | -12.21% | US#874/3,121 Sec#59/266 |
| 1Y MDD | -21.75% | US#831/3,121 Sec#36/266 |
| Trading | ||
| Volume | 999,543 shares | US#1,560/3,121 Sec#171/266 |
| Trading Value | $17M | US#2,137/3,121 Sec#171/266 |
| Per Share | ||
| EPS | $2.44 | US#1,201/3,121 Sec#33/266 |
| BPS | $4.78 | US#2,300/3,121 Sec#133/266 |
Company Info
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.